| Vivani Medical Provides Business Update Including $3M Equity Financing and Reports First Quarter 2025 Financial Results |
All subjects in the NPM-115 cohort had successful insertions of a miniature, ultra long-acting GLP-1 (exenatide) implant in the on-going LIBERATE-1™ study in obese or overweight individuals; top-line results are anticipated in mid-2025 |
globenewswire.com |
2025-05-13 20:30:00 |
Czytaj oryginał (ang.) |
| Vivani Medical to Present at the American Association of Pharmaceutical Scientists' “Beyond GLP1s: Where the Science will Take Business Next” Virtual Workshop |
ALAMEDA, Calif., May 07, 2025 (GLOBE NEWSWIRE) -- Vivani Medical, Inc. (NASDAQ: VANI) (the “Company” or “Vivani”), a clinical-stage biopharmaceutical company developing miniature, ultra long-acting drug implants, announced today that CEO Adam Mendelsohn, Ph.D., will present and participate in a panel discussion at the American Association of Pharmaceutical Scientists' (AAPS) “Beyond GLP1s: Where the Science will Take Business Next” Virtual Workshop, taking place from May 13-14, 2025. |
globenewswire.com |
2025-05-07 12:30:00 |
Czytaj oryginał (ang.) |
| Vivani Medical and Okava Expand Collaboration to Develop OKV-119 for Dogs, Targeting Metabolic Health and Longevity |
Over half of all dogs in the United States today are overweight or obese, placing them at increased risk for chronic diseases, metabolic decline and shortened lifespans Over half of all dogs in the United States today are overweight or obese, placing them at increased risk for chronic diseases, metabolic decline and shortened lifespans |
globenewswire.com |
2025-04-15 12:30:00 |
Czytaj oryginał (ang.) |
| Vivani Medical Provides Business Update and Reports Fourth Quarter and Full Year 2024 Financial Results |
Successful initial administration and full enrollment in first-in-human LIBERATE-1 ™ study of NPM-115 (exenatide implant) in obese and overweight subjects with top-line data expected in mid-2025 |
globenewswire.com |
2025-03-31 11:30:00 |
Czytaj oryginał (ang.) |
| Vivani Medical Announces $8.25M Private Placement Equity Financing |
Financing strengthens balance sheet, extending expected runway into the second quarter of 2026 Enables accelerated development of NPM-139, Company's once or twice-yearly GLP-1 (semaglutide) implant under development for chronic weight management ALAMEDA, Calif., March 27, 2025 (GLOBE NEWSWIRE) -- Vivani Medical, Inc. (Nasdaq: VANI) (“Vivani” or the “Company”), a clinical-stage biopharmaceutical company developing miniature, ultra long-acting drug implants, today announced that it has entered into a securities purchase agreement to issue and sell an aggregate of 7,366,071 shares, each at a price of $1.12 per share, expected to result in gross proceeds of approximately $8.25 million in a private placement. |
globenewswire.com |
2025-03-27 09:32:00 |
Czytaj oryginał (ang.) |
| Vivani Medical Announces Positive Preclinical Weight Loss Data for NPM-139 Semaglutide Implant, with Potential for Once-Yearly Dosing |
NanoPortal™ technology successfully delivers semaglutide, the active ingredient in Ozempic®/Wegovy®, in a preclinical study with NPM-139 (semaglutide implant) |
globenewswire.com |
2025-03-26 09:30:00 |
Czytaj oryginał (ang.) |
| Vivani Medical to Present at the Emerging Growth Conference on March 27, 2025 |
ALAMEDA, Calif.--(BUSINESS WIRE)--Vivani Medical, Inc. (NASDAQ: VANI) (“Vivani” or the “Company”), a clinical-stage biopharmaceutical company developing miniature, ultra long-acting drug implants, announced today that it will present at the Emerging Growth Conference on March 27, 2025. Vivani welcomes individual and institutional investors, along with advisors and analysts, to join its interactive presentation. This live online event will offer existing shareholders and the investment community. |
businesswire.com |
2025-03-24 10:30:00 |
Czytaj oryginał (ang.) |
| What Makes Vivani Medical (VANI) a New Buy Stock |
Vivani Medical (VANI) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy). |
zacks.com |
2025-03-17 15:00:23 |
Czytaj oryginał (ang.) |
| Vivani Medical Achieves First Implant and Full Enrollment in the First-in-Human Clinical Trial of GLP-1 Implant NPM-115 in Obese or Overweight Adults |
ALAMEDA, Calif.--(BUSINESS WIRE)--Vivani Medical, Inc. (NASDAQ: VANI) (“Vivani” or the “Company”), a clinical-stage biopharmaceutical company developing miniature, ultra long-acting drug implants, today announced the successful administration of its first GLP-1 (exenatide) implant in the LIBERATE-1™ clinical trial. This milestone marks a critical step toward addressing one of healthcare's most pressing challenges: medication adherence in metabolic diseases including chronic weight management an. |
businesswire.com |
2025-03-13 09:30:00 |
Czytaj oryginał (ang.) |
| Vivani Medical Announces Intent to Spin Off Cortigent Neurostimulation Business |
ALAMEDA, Calif.--(BUSINESS WIRE)--Vivani Medical, Inc. (NASDAQ: VANI) (“Vivani” or the “Company”), a clinical-stage biopharmaceutical company developing miniature, ultra long-acting drug implants, today announced that it intends to spin off Cortigent, Inc., a division that develops brain implant devices to help people recover critical body functions, as an independent publicly-traded company. The strategic goal of this transaction is to create two focused companies dedicated to driving current. |
businesswire.com |
2025-03-12 10:30:00 |
Czytaj oryginał (ang.) |
| EXCLUSIVE: Vivani Medical To Spin Off Cortigent Neurostimulation Business To Create Better Focus On Individual Entities And Shareholder Value |
On Wednesday, Vivani Medical, Inc. VANI said it intends to spin off Cortigent, Inc., a division that develops brain implant devices to help people recover critical body functions, as an independent publicly-traded company. |
benzinga.com |
2025-03-12 10:00:45 |
Czytaj oryginał (ang.) |
| Vivani reports start of first human trial of GLP-1 implant, says H.C. Wainwright |
H.C. Wainwright reiterates a Buy rating and $4 price target on Vivani Medical shares after the company announced that the first-in-human clinical trial of NPM-115, an exenatide implant based on the company's NanoPortal platform technology, has started patient screening and enrollment at two clinical sites in Australia. The firm believes that NPM-115 has the potential to show comparable efficacy to semaglutide with twice-yearly administration, the analyst tells investors in a research note. In addition, H.C. Wainwright thinks the company could choose to raise additional capital within the next 12 months. |
https://thefly.com |
2024-12-20 14:17:28 |
Czytaj oryginał (ang.) |
| Vivani Medical Announces Initiation of First in Human Clinical Trial with GLP-1 Implant in Obese and Overweight Individuals in Australia |
ALAMEDA, Calif.--(BUSINESS WIRE)--Vivani Medical, Inc. (Nasdaq: VANI) (“Vivani” or the “Company”), an innovative biopharmaceutical company developing novel, ultra long-acting drug implants, today announced that screening and enrollment of the first-in-human clinical trial, known as LIBERATE-1™, has been initiated at two centers in Australia to investigate the safety, tolerability and full pharmacokinetic profile of an exenatide implant. This study is the first clinical application of the Compan. |
businesswire.com |
2024-12-19 10:30:00 |
Czytaj oryginał (ang.) |
| Vivani Medical to Present at the Innovation in Obesity Therapeutics Summit West Coast |
ALAMEDA, Calif.--(BUSINESS WIRE)--Vivani Medical, Inc. (NASDAQ: VANI) (the “Company” or “Vivani”), an innovative biopharmaceutical company developing miniaturized, ultra long-acting drug implants, announced today that CEO Adam Mendelsohn, Ph.D., will present and participate in a panel discussion at the Innovation in Obesity Therapeutics Summit West Coast, taking place in San Diego, California, from December 10-12, 2024. Event details are as follows: Panel Discussion: The Obesity Race on the Man. |
businesswire.com |
2024-12-04 10:30:00 |
Czytaj oryginał (ang.) |
| Vivani Medical Receives Regulatory Approval to Initiate First in Human Clinical Trial with GLP-1 Implant in Obese and Overweight Individuals in Australia |
ALAMEDA, Calif.--(BUSINESS WIRE)--Vivani Medical, Inc. (Nasdaq: VANI) (“Vivani” or the “Company”), an innovative, biopharmaceutical company developing novel, ultra long-acting drug implants, today announced that the Bellberry Human Research Ethics Committee (“HREC”) has approved and the Therapeutic Goods Administration (“TGA”) in Australia has formally acknowledged a first in human clinical trial of the Company's miniature, subdermal GLP-1 (exenatide) implant in obese and overweight subjects. T. |
businesswire.com |
2024-09-26 12:30:00 |
Czytaj oryginał (ang.) |
| Vivani Medical to Present at the Emerging Growth Conference on September 25, 2024 |
ALAMEDA, Calif.--(BUSINESS WIRE)--Vivani Medical, Inc. (NASDAQ: VANI) (the “Company” or “Vivani”), an innovative biopharmaceutical company developing miniaturized, ultra long-acting drug implants, announced today that it will present at the Emerging Growth Conference on September 25, 2024. Vivani invites individual and institutional investors as well as advisors and analysts to attend its interactive presentation at the Emerging Growth Conference. This live, interactive online event will give e. |
businesswire.com |
2024-09-23 12:57:00 |
Czytaj oryginał (ang.) |
| Vivani Medical to Participate in the H.C. Wainwright 26th Annual Global Investment Conference |
ALAMEDA, Calif.--(BUSINESS WIRE)--Vivani Medical, Inc. (Nasdaq: VANI) (“Vivani” or the “Company”), an innovative biopharmaceutical company developing miniature, ultra long-acting, subdermal drug implants, today announced its plans to participate in the H.C. Wainwright 26th Annual Global Investment Conference taking place September 9-11, 2024 in New York, New York. Vivani's Chief Executive Officer, Adam Mendelsohn, Ph.D., will host one-on-one meetings with investors at the Conference in addition. |
businesswire.com |
2024-08-28 23:10:00 |
Czytaj oryginał (ang.) |
| Vivani Medical Announces FDA Clears Investigational New Drug Application and Lifts Clinical Hold for NPM-119, a Miniature Long-Term Subdermal GLP-1 Drug Implant |
ALAMEDA, Calif.--(BUSINESS WIRE)--Vivani Medical, Inc. (Nasdaq: VANI) (“Vivani” or the “Company”), an innovative, biopharmaceutical company developing novel, long-term drug implants, today announced the U.S. Food and Drug Administration has cleared the Investigational New Drug Application (“IND”) and lifted the clinical hold on NPM-119 to allow initiation of LIBERATE-1™, a Phase 1 clinical trial to assess the safety, tolerability and pharmacokinetics of NPM-119 (exenatide), the Company's miniat. |
businesswire.com |
2024-06-13 12:00:00 |
Czytaj oryginał (ang.) |
| Vivani Medical Announces Publication of Positive Weight Loss Data Supporting Potential Veterinary Use of OKV-119 Miniature, Long-term GLP-1 Implant |
ALAMEDA, Calif.--(BUSINESS WIRE)--Vivani Medical, Inc. (Nasdaq: VANI) (“Vivani” or the “Company”), a biopharmaceutical company developing miniaturized, long-term drug implants including its lead asset NPM-115 for chronic weight management in obese or overweight human patients with one or more risk factors, today announced the publication of positive proof-of-concept weight loss data with OKV-119, a miniature, subdermal, exenatide drug implant designed to treat feline obesity and diabetes, in th. |
businesswire.com |
2024-05-28 12:00:00 |
Czytaj oryginał (ang.) |
| VANI Stock Earnings: Vivani Medical Meets EPS for Q1 2024 |
Vivani Medical (NASDAQ: VANI ) just reported results for the first quarter of 2024. Vivani Medical reported earnings per share of -12 cents. |
investorplace.com |
2024-05-14 00:52:51 |
Czytaj oryginał (ang.) |
| Vivani Medical Provides Business Update and Reports First Quarter 2024 Financial Results |
ALAMEDA, Calif.--(BUSINESS WIRE)--Vivani Medical, Inc. (Nasdaq: VANI) (“Vivani” or the “Company”), a biopharmaceutical company developing miniaturized, long-term drug implants including its lead asset NPM-115 for chronic weight management in obese or overweight patients with one or more risk factors, today reported financial results for the first quarter ended March 31, 2024, and provided a business update. Adam Mendelsohn, Ph.D., Vivani's Chief Executive Officer, stated, “Since pivoting to pri. |
businesswire.com |
2024-05-13 20:45:00 |
Czytaj oryginał (ang.) |
| Vivani Medical Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial Results |
ALAMEDA, Calif.--(BUSINESS WIRE)--Vivani Medical, Inc. (Nasdaq: VANI) (“Vivani” or the “Company”), a biopharmaceutical company developing miniaturized, long-term drug implants including its lead asset NPM-115 for chronic weight management in obese or overweight patients with one or more risk factors, today reported financial results for the fourth quarter and full year ended December 31, 2023, and provided a business update. Adam Mendelsohn, Ph.D., Vivani's Chief Executive Officer, stated, “202. |
businesswire.com |
2024-03-26 10:30:00 |
Czytaj oryginał (ang.) |
| Vivani Medical Appoints Daniel Bradbury to its Board of Directors |
ALAMEDA, Calif.--(BUSINESS WIRE)--Vivani Medical, Inc. (Nasdaq: VANI) (“Vivani” or the “Company”), an innovative, preclinical-stage biopharmaceutical company developing novel, long-term drug implants, today announced the appointment of long-time industry veteran Daniel Bradbury to its Board of Directors. “Dan has served as an advisor to Vivani and our legacy company, Nano Precision Medical, since 2017, and his guidance has been invaluable,” said Adam Mendelsohn, Ph.D., Vivani President and Chie. |
businesswire.com |
2024-03-06 10:00:00 |
Czytaj oryginał (ang.) |
| Vivani Medical Surges on its Ozempic-Like Weight-Loss Implant |
The Ozempic craze continues to make headlines in the medical sector, and GLP-1 drug stocks continue to surge higher. Shares of Ozempic and Wegovy makers Novo Nordisk A/S NYSE: NVO are already up 20% year-to-date (YTD). |
marketbeat.com |
2024-03-06 08:14:02 |
Czytaj oryginał (ang.) |
| Vivani Medical Announces Pricing of $15.0 Million Registered Direct Offering of Common Stock and Warrants |
ALAMEDA, Calif.--(BUSINESS WIRE)--Vivani Medical, Inc. (Nasdaq: VANI) ("Vivani" or the "Company"), an innovative, preclinical-stage biopharmaceutical company developing novel, long-term drug implants, today announced that it has entered into a securities purchase agreement with an institutional investor to purchase 3,947,368 shares of common stock and warrants to purchase up to an aggregate of 3,947,368 shares of common stock at a purchase price of $3.80 per share and accompanying warrant in a. |
businesswire.com |
2024-03-01 09:49:00 |
Czytaj oryginał (ang.) |
| Vivani Medical (VANI) stock price surged: is it a good buy? |
Vivani Medical (NASDAQ: VANI) stock price surged hard this week after the company published positive results of its ongoing weight loss drug trial. The shares surged from about $1 and reached a high of $7.81. |
invezz.com |
2024-02-29 09:25:52 |
Czytaj oryginał (ang.) |
| Why Is Vivani Medical (VANI) Stock Up 300% Today? |
Little-known emerging biopharmaceutical company Vivani Medical (NASDAQ: VANI ) saw its market value increase dramatically on Wednesday. Catapulting sentiment was the company's weight-loss solution, which offered compelling results compared to mainline weight-loss therapeutics. |
investorplace.com |
2024-02-28 15:59:21 |
Czytaj oryginał (ang.) |
| Vivani Medical Announces Positive NPM-115 Preclinical Weight Loss Data Comparable to Ozempic®/Wegovy® and Discloses NPM-139 as Semaglutide as Strategy Shifts to Prioritize Obesity Portfolio |
ALAMEDA, Calif.--(BUSINESS WIRE)--Vivani Medical, Inc. (Nasdaq: VANI) (“Vivani” or the “Company”), an innovative, preclinical-stage biopharmaceutical company developing novel, long-term drug implants, today announced positive preclinical data on weight loss effects for NPM-115, the Company's miniature, twice-yearly, exenatide implant under development for the treatment of chronic weight management. The Company also disclosed that semaglutide is the active pharmaceutical ingredient in NPM-139, a. |
businesswire.com |
2024-02-28 10:30:00 |
Czytaj oryginał (ang.) |
| Vivani Medical Provides Business Update and Reports Third Quarter Financial Results |
ALAMEDA, Calif.--(BUSINESS WIRE)--Vivani Medical, Inc. (Nasdaq: VANI) (“Vivani” or the “Company”), an innovative, preclinical-stage biopharmaceutical company developing novel, long-term drug implants, today reported financial results for the third quarter of 2023 and provided a business update. Vivani™ continues to advance its emerging pipeline of innovative, highly differentiated drug implants leveraging its proprietary NanoPortal™ subdermal implant technology designed to guarantee medication. |
businesswire.com |
2023-11-14 08:00:00 |
Czytaj oryginał (ang.) |
| Vivani Medical to Present at BIO Investor Forum |
ALAMEDA, Calif.--(BUSINESS WIRE)--Vivani Medical, Inc. (NASDAQ: VANI) (the “Company” or “Vivani”), an innovative, preclinical-stage biopharmaceutical company that develops novel, long-term drug implants, announced today that it will present at the BIO Investor Forum at 2:00 p.m. PDT at the Hilton San Francisco Union Square on October 18, 2023. Vivani President and Chief Executive Officer Adam Mendelsohn, Ph.D., will provide updates on the company, its proprietary NanoPortal™ implant technology. |
businesswire.com |
2023-10-16 10:00:00 |
Czytaj oryginał (ang.) |
| Vivani Medical to Present at the Boulder Peptide Symposium |
ALAMEDA, Calif.--(BUSINESS WIRE)--Vivani Medical, Inc. (NASDAQ: VANI) (the “Company” or “Vivani”), an innovative, preclinical-stage biopharmaceutical company that develops novel, long-term drug implants, announced today that it will present at the upcoming Annual Boulder Peptide Symposium at 11:20 am PST at the Napa Valley Marriott Hotel and Spa in Napa, California on September 19, 2023. Dr. Adam Mendelsohn, CEO, will provide updates on the company, its proprietary NanoPortal™ implant technolog. |
businesswire.com |
2023-09-07 10:00:00 |
Czytaj oryginał (ang.) |